CHNC China Infrastructure Construct

CHNC Ventures Into Latin American Country for Extension of Its Clinical Research Facilities

CHNC Ventures Into Latin American Country for Extension of Its Clinical Research Facilities

HOUSTON, TX, Oct. 25, 2021 (GLOBE NEWSWIRE) -- via – China Infrastructure Construction Corp. (OTC: CHNC) (dba Cannabis Bioscience International Holdings) announces the expansion of its clinical research services to Latin America with a new agreement/alliance with QUIASMO, an IPS medical clinic based in Bogotá, Colombia. 

“Not only has Alpha Research Institute expanded the services offered to Puerto Rico, but it is our pleasure to announce that we have also signed a contract with a clinic in Bogota, Colombia that will serve as an extension for Alpha in Latin America. QUIASMO is a medical clinic with a wide range of services that cover infectiology, family medicine, general medicine, nutrition, psychology, nursery and sample collection,” says Anne Graham, CHNC’s CLO.

The interdisciplinary team of highly qualified professionals of the clinic is led by Dr. John Jairo Carvajal, with a Master’s degree in HIV Management. As well, Dr. Carvajal possesses great knowledge in the integral comprehensive care of catastrophic pathologies. His expertise, alongside the technology and equipment available, allows this health clinical center to properly adapt to the design and structure of many investigation projects.

This is a logical step for CHNC in the right direction. “In order for us to grow as a company, we need to continue to expand to International Markets and identify new areas where we can share our knowledge,” adds Dr. Deepika Deol, Alpha Research Institute Clinical Director.

CHNC expects to meet the needs of big pharmaceutical companies looking to perform clinical investigations in Latin American countries with this new medical attention center in Colombia. Expanding the grasp of our services into the Colombian market will allow us to provide its community with life-changing treatments and scientific development in a wide range of therapeutic areas. 

To learn more visit:  

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:



817/528-2475 for English

214/733-0868 for Spanish



EN
25/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 ...

Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operati...

 PRESS RELEASE

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr....

Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz a...

 PRESS RELEASE

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accele...

Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to resche...

 PRESS RELEASE

CBIH Announces New Patent Initiative Targeting Opioid Addiction Throug...

Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, a...

 PRESS RELEASE

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Op...

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch